Study: Drug developers routinely–and unethically–leave trial data in the dark

John Carroll

companies routinely herald their concern for patients as the leading reason why they spend billions of dollars on research. But a new questions Big Pharma's real commitment to its ethical obligations to patients when companies routinely neglect to publish the results of clinical trials.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS